- Home
- ARWR vs CELC Comparison
ARWR vs CELC Comparison
Compare ARWR & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARWR
- CELC
- Stock Information
- Founded
- ARWR 2003
- CELC 2011
- Country
- ARWR United States
- CELC United States
- Employees
- ARWR N/A
- CELC N/A
- Industry
- ARWR Biotechnology: Pharmaceutical Preparations
- CELC Medical Specialities
- Sector
- ARWR Health Care
- CELC Health Care
- Exchange
- ARWR Nasdaq
- CELC Nasdaq
- Market Cap
- ARWR 2.5B
- CELC 2.3B
- IPO Year
- ARWR 1993
- CELC 2017
- Fundamental
- Price
- ARWR $31.51
- CELC $55.03
- Analyst Decision
- ARWR Strong Buy
- CELC Strong Buy
- Analyst Count
- ARWR 8
- CELC 5
- Target Price
- ARWR $47.75
- CELC $53.60
- AVG Volume (30 Days)
- ARWR 2.8M
- CELC 867.1K
- Earning Date
- ARWR 08-07-2025
- CELC 11-13-2025
- Dividend Yield
- ARWR N/A
- CELC N/A
- EPS Growth
- ARWR N/A
- CELC N/A
- EPS
- ARWR N/A
- CELC N/A
- Revenue
- ARWR $572,976,000.00
- CELC N/A
- Revenue This Year
- ARWR $21,619.52
- CELC N/A
- Revenue Next Year
- ARWR N/A
- CELC N/A
- P/E Ratio
- ARWR N/A
- CELC N/A
- Revenue Growth
- ARWR 2816.20
- CELC N/A
- 52 Week Low
- ARWR $9.57
- CELC $7.58
- 52 Week High
- ARWR $31.59
- CELC $63.06
- Technical
- Relative Strength Index (RSI)
- ARWR 75.77
- CELC 58.19
- Support Level
- ARWR $28.12
- CELC $52.90
- Resistance Level
- ARWR $31.13
- CELC $56.27
- Average True Range (ATR)
- ARWR 1.64
- CELC 3.21
- MACD
- ARWR 0.17
- CELC -1.15
- Stochastic Oscillator
- ARWR 98.90
- CELC 36.37
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.